EP0380370A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Inhibiting tumour recurrence after surgical resection
Assignee: Boston Children's Hospital
•
Filing: 1990-01-26
•
Granted: —
•
Expires: 2010-01-26
Abstract
Abstract To inhibit recurrence of a tumour at a local site in a mammal in conjunction with the resection of tissue at the site, there is applied to the site a composition which includes an agent for inhibiting attachment of a tumour cell in the area of the tissue. Preferably the agent is chosen from L-azetidine-2-carboxylic acid, Dispase, and a synthetic fibronectin peptide containing an arginine-glycine-aspartate sequence.
Inventors
- 👤 Giles F. Whalen
- 👤 Donald E. Ingber
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 09:37
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/08; A61K31/00; A61K31/33; A61K31/395; A61K38/16; A61K38/17; A61K38/39; A61K38/43; A61K38/46; A61K38/465; A61K38/47; A61K38/48; A61K38/482; A61K38/4826; A61K38/4886; A61P; A61P35/00; A61P43/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
62 words
A method for inhibiting recurrence of a tumor at a local site in a mammal in conjunction with resection of tissue at said site, said method comprising the steps of: a) resecting an area of tissue from said site, b) applying to said site a composition comprising an agent for inhibiting attachment of a tumor cell in the area of said tissue.
Claim 2
Independent Claim
62 words
A method for inhibiting recurrence of a tumor at a local site in a mammal in conjunction with resection of tissue at said site, said method comprising the steps of: a) resecting an area of tissue from said site, b) applying to said site a composition comprising an agent for inhibiting attachment of a tumor cell in the area of said tissue.
Claim 3
Dependent Claim
41 words
The method of claim 1 wherein said method comprises applying a composition comprising an agent which does not kill said tumor cell, inhibits said attachment of said tumor cell, and is relatively non-toxic to cells in the area of said tissue.
Claim 4
Dependent Claim
46 words
The method of claim 2 wherein said agent is chosen from a group consisting of (a) modulators of extracellular matrix metabolism, (b) proteolytic enzymes, (c) high molecular weight polymers, and (d) synthetic peptides or saccharides containing a cell binding sequence of a specific extracellular matrix molecule.
Claim 5
Dependent Claim
30 words
The method of claim 3 wherein said agent is chosen from the group consisting of (a) L-azetidine-2-carboxylic acid, (b) Dispase, and (c) a synthetic fibronectin peptide containing an arginine-glycine-aspartate sequence.
Claim 6
Dependent Claim
18 words
The method of claim 1, wherein said composition is applied to said mammal in combination with an immunostimulant.
Claim 7
Dependent Claim
17 words
The method of claim 5, where said immunostimulant and said composition are applied simultaneously to said mammal.
Claim 8
Dependent Claim
20 words
The method of claim 1 in which said agent comprises an enzyme which inhibits the attachment of said tumor cell.
Claim 9
Dependent Claim
17 words
The method of claim 7 in which said enzyme is capable of disrupting adhesive contacts of cells.
Claim 10
Dependent Claim
13 words
The method of claim 1 in which said agent comprises a proteolytic enzyme.
Claim 11
Dependent Claim
16 words
The method of Claim 1 in which said agent comprises dispase, trypsin, pancreatin, collagenase or thermolysin.
Claim 12
Dependent Claim
17 words
The method of Claim 1 in which said agent comprises a glycosidase, preferably heparinase, sialdase or mannosidase.
Claim 13
Dependent Claim
18 words
The method of Claim 1 in which said agent is a synthetic fibronectin peptide containing an arginine-glycine-aspartate sequence.
Claim 14
Dependent Claim
16 words
The method of Claim 7 in which said agent comprises the sequences GRGDS, GRGES, or Gly-Pen-Gly-Arg-Gly-Asp-Ser-Pro-Cys-Ala.
Claim 15
Dependent Claim
16 words
The method of Claim 1 in which said agent comprises GRGDSP, GRGESP, RGDS, GRGDS or Gly-Pen-Gly-Arg-Gly-Asp-Ser-Pro-Cys-Ala.
Claim 16
Dependent Claim
2 words
L-azetidine-2-carboxylic acid.
Claim 17
Dependent Claim
2 words
L-azetidine-2-carboxylic acid.
Claim 18
Dependent Claim
8 words
A synthetic fibronectin peptide containing an arginine-glycine-aspartate sequence.
Claim 19
Dependent Claim
8 words
A synthetic fibronectin peptide containing an arginine-glycine-aspartate sequence.
Claim 20
Dependent Claim
52 words
An enzyme adapted operatively to inhibit recurrence of a tumor at a local site in a mammal in conjunction with resection of tissue at said site and comprising: dispase; trypsin; pancreatin; collagenase; a glycosidase, preferably heparinase, sialdase or mammosidase; or thermolysin; said enzyme being for use in surgery involving resection of tissue.
Claim 21
Dependent Claim
52 words
An enzyme adapted operatively to inhibit recurrence of a tumor at a local site in a mammal in conjunction with resection of tissue at said site and comprising: dispase; trypsin; pancreatin; collagenase; a glycosidase, preferably heparinase, sialdase or mammosidase; or thermolysin; said enzyme being for use in surgery involving resection of tissue.
Claim 22
Dependent Claim
42 words
For use in the manufacture of a medicament for use in surgery involving resection of tissue at a local site in a mammal to inhibit recurrence of a tumour at said site, any of the agents identified in Claims 13 to 17.
Claim 23
Dependent Claim
72 words
An agent selected from modulators of extracellular matrix metabolism, degradative enzymes, high molecular weight compounds that produce high medium viscosity, and agents effective to act on cell surfaces and interfere with binding to extracellular molecules or other cell surfaces, all for use in the manufacture of a medicament for use in inhibiting recurrence of a tumour at a local site in a mammal in conjunction with resection of tissue at said site.
Claim 24
Dependent Claim
72 words
An agent selected from modulators of extracellular matrix metabolism, degradative enzymes, high molecular weight compounds that produce high medium viscosity, and agents effective to act on cell surfaces and interfere with binding to extracellular molecules or other cell surfaces, all for use in the manufacture of a medicament for use in inhibiting recurrence of a tumour at a local site in a mammal in conjunction with resection of tissue at said site.
Claim 25
Dependent Claim
35 words
An agent as identified in any of Claims 13 to 16, for use in inhibiting recurrence of a tumour at a local site in a mammal in conjunction with resection of tissue at said site.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.